Hemostatic therapy as a management strategy for acquired hemophilia: what does the future hold?

References

• Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, et al. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003;121:21–35.
   PubMed Web of Science ®Google Scholar
• Cohen AJ, Kessler CM. Acquired inhibitors. Bailleres Clin Haematol. 1996;9:331–354.
   PubMed Web of Science ®Google Scholar
• Franchini M, Vaglio S, Marano G, et al. Acquired hemophilia A: a review of recent data and new therapeutic options. Hematology. 2017;25:1–7.
   Google Scholar
• Franchini M, Mannucci PM. Acquired haemophilia A: a 2013 update. Thromb Haemost. 2013;110:1114–1120.
   PubMed Web of Science ®Google Scholar
• Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood. 2008;112:250–255.
   PubMed Web of Science ®Google Scholar
• Franchini M, Gandini G, Di Paolantonio T, et al. Acquired hemophilia A: a concise review. Am J Hematol. 2005;80:55–63.
   PubMed Web of Science ®Google Scholar
• Franchini M, Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis. 2012;7:24.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Mannucci PM, Garagiola I, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med. 2016;374:2054–2064.
   PubMed Web of Science ®Google Scholar
• Coppola A, Favaloro EJ, Tufano A, et al. Acquired inhibitors of coagulation factors: part I – acquired hemophilia A. Semin Thromb Hemost. 2012;38:433–446.
   PubMed Web of Science ®Google Scholar
• Collins PW, Hirsch S, Baglin TP, et al. for the UK Haemophilia Centre Doctors’ Organisation. Acquired haemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood. 2007;109:1870–1877.
   PubMed Web of Science ®Google Scholar
• Knoebl P, Marco P, Baudo F, et al. on behalf of the EACH2 Registry Contributors. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012;10:622–631.
   PubMed Web of Science ®Google Scholar
• Franchini M, Zaffanello M, Lippi G. Acquired hemophilia in pediatrics: a systematic review. Pediatr Blood Cancer. 2010;55:606–611.
   PubMed Web of Science ®Google Scholar
• Solymoss S. Postpartum acquired factor VIII inhibitors: results of a survey. Am J Haematol. 1998;59:1–4.
   PubMed Web of Science ®Google Scholar
• Franchini M. Postpartum acquired factor VIII inhibitors. Am J Hematol. 2006;81:768–773.
   PubMed Web of Science ®Google Scholar
• Tengborn L, Baudo F, Huth-Kühne A, et al. on behalf of the EACH2 Registry Contributors. Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry. BJOG. 2012;119:1529–1537.
   PubMed Web of Science ®Google Scholar
• Tiede A, Klamroth R, Scharf RE, et al. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood. 2015;125:1091–1097.
   PubMed Web of Science ®Google Scholar
• Kessler CM, Ma AD, Al-Mondhiry HA, et al. Assessment of acquired hemophilia patient demographics in the United States: the hemostasis and thrombosis research society registry. Blood Coagul Fibrinolysis. 2016;27:761–769.
   PubMed Web of Science ®Google Scholar
• Sun B, Xue F, Feng Y, et al. Outcome of CARE: a 6-year national registry of acquired haemophilia A in China. Br J Haematol. 2019;187:653–665.
   PubMed Web of Science ®Google Scholar
• Franchini M, Capra F, Nicolini N, et al. Drug-induced anti-factor VIII antibodies: a systematic review. Med Sci Monit. 2007;13:RA55–61.
   PubMed Web of Science ®Google Scholar
• Franchini M, Glingani C, De Donno G, et al. The first case of acquired hemophilia A associated with SARS-CoV-2 infection. Am J Hematol. 2020;95:E197–8.
   PubMed Web of Science ®Google Scholar
• Huth-Kühne A, Baudo F, Collins P, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica. 2009;94:566–575.
   PubMed Web of Science ®Google Scholar
• Franchini M, Castaman G, Coppola A, et al. AICE Working Group. Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management. Blood Transfus. 2015;13:498–513.
   PubMed Web of Science ®Google Scholar
• Collins PW, Chalmers E, Hart D, et al. Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO. Br J Haematol. 2013;162:758–773.
   PubMed Web of Science ®Google Scholar
• Tiede A, Collins P, Knoebl P, et al. International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica. 2020;105:1791–1801.
   PubMed Web of Science ®Google Scholar
• Kershaw G, Jayakodi D, Dunkley S. Laboratory identification of factor inhibitors: the perspective of a large tertiary hemophilia center. Semin Thromb Hemost. 2009;35:760–768.
   PubMed Web of Science ®Google Scholar
• Kershaw G, Orellana D. Mixing tests: diagnostic aides in the investigation of prolonged prothrombin times and activated partial thromboplastin times. Semin Thromb Hemost. 2013;39:283–290.
   PubMed Web of Science ®Google Scholar
• Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost. 2009;7:1737–1740.
   PubMed Web of Science ®Google Scholar
• Tripodi A, Mancuso ME, Chantarangkul V, et al. Lupus anticoagulants and their relationship with the inhibitors against coagulation factor VIII: considerations on the differentiation between the 2 circulating anticoagulants. Clin Chem. 2005;51:1883–1885.
   PubMed Web of Science ®Google Scholar
• Tiede A, Werwitzke S, Scharf RE. Laboratory diagnosis of acquired hemophilia A: limitations, consequences and challenges. Semin Thromb Hemost. 2014;4:803–811.
   Google Scholar
• Verbruggen B, Novakova I, Wessels H, et al. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost. 1995;73:247–251.
   PubMed Web of Science ®Google Scholar
• Werwitzke S, Geisen U, Nowak-Goettl U, et al. Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01/2010 study. J Thromb Haemost. 2016;14:940–947.
   PubMed Web of Science ®Google Scholar
• Kruse-Jarres R, Kempton CL, Baudo F, et al. Acquired hemophilia A: updated review of evidence and treatment guidance. Am J Hematol. 2017;92:695–705.
   PubMed Web of Science ®Google Scholar
• Windyga J, Baran B, Odnoczko E, et al. Guidelines for acquired hemophilia A. Ginekol Pol. 2019;90:353–364.
   PubMed Web of Science ®Google Scholar
• Tiede A, Giangrande P, Teitel J, et al. Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: a global expert consensus statement. Haemophilia. 2019;25:969–978.
   PubMed Web of Science ®Google Scholar
• Collins P, Baudo F, Knoebl P, et al. EACH2 registry collaborators. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood. 2012;120:47–55.
   PubMed Web of Science ®Google Scholar
• Green D, Rademaker AW, Briët E. A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost. 1993;70:753–757.
   PubMed Web of Science ®Google Scholar
• Bitting RL, Bent S, Li Y, et al. The prognosis and treatment of acquired hemophilia: a systematic review and meta-analysis. Blood Coagul Fibrinolysis. 2009;20:517–523.
   PubMed Web of Science ®Google Scholar
• Rezaieyazdi Z, Mansouritorghabeh H. Clinical care of bone health in patients on the immune tolerance induction’s protocols with an immunosuppressive agent for inhibitor eradication in hemophilia. Clin Appl Thromb Hemost. 2020 Jan–Dec;26:1076029620913951.
   Web of Science ®Google Scholar
• Franchini M, Mannucci PM. Inhibitor eradication with rituximab in haemophilia: where do we stand? Br J Haematol. 2014;165:600–608.
   PubMed Web of Science ®Google Scholar
• Franchini M. Rituximab in the treatment of adult acquired hemophilia A: a systematic review. Crit Rev Oncol Hematol. 2007;63:47–52.
   PubMed Web of Science ®Google Scholar
• Sperr WR, Lechner K, Pabinger I. Rituximab for the treatment of acquired antibodies to factor VIII. Haematologica. 2007;92:66–72.
   PubMed Web of Science ®Google Scholar
• Borg JY, Guillet B, Le Cam-Duchez V, et al. SACHA Study Group. Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l’Hémophilie Acquise) registry. Haemophilia. 2013;19(4):564–570.
   PubMed Web of Science ®Google Scholar
• Turecek PL, Váradi K, Gritsch H, et al. FEIBA: mode of action. Haemophilia. 2004;10(Suppl 2):3–9.
   PubMed Web of Science ®Google Scholar
• Sallah S. Treatment of acquired haemophilia with factor eight inhibitor bypassing activity. Haemophilia. 2004;10:169–173.
   PubMed Web of Science ®Google Scholar
• Franchini M, Lippi G. Recombinant activated factor VII: mechanisms of action and current indications. Semin Thromb Hemost. 2010;36:485–492.
   PubMed Web of Science ®Google Scholar
• Franchini M, Coppola A, Tagliaferri A, et al. FEIBA versus NovoSeven in hemophilia patients with inhibitors. Semin Thromb Hemost. 2013;39:772–778.
   PubMed Web of Science ®Google Scholar
• Zanon E, Pasca S, Santoro C, et al. Activated prothrombin complex concentrate (FEIBA) in acquired haemophilia A: a large multicentre Italian study - the FAIR Registry. Br J Haematol. 2019;184:853–855.
   PubMed Web of Science ®Google Scholar
• Hay CRM, Negrier C, Ludlam CA. The treatment of bleeding in acquired hemophilia with recombinant factor VIIa: a multicenter study. Thromb Haemost. 1997;78:3–7.
   Web of Science ®Google Scholar
• Baudo F, Collins P, Huth-Kühne A, et al. on behalf of the EACH2 registry contributors. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood. 2012;120:39–46.
   PubMed Web of Science ®Google Scholar
• Mancuso ME, Fasulo MR. Thrombin generation assay as a laboratory monitoring tool during bypassing therapy in patients with hemophilia and inhibitors. Semin Thromb Hemost. 2016;42:30–35.
   PubMed Web of Science ®Google Scholar
• Hoffman M, Dargaud Y. Mechanisms and monitoring of bypassing agent therapy. J Thromb Haemost. 2012;10:1478–1485.
   PubMed Web of Science ®Google Scholar
• Sumner MJ, Geldziler BD, Pedersen M, et al. Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal. Haemophilia. 2007;13:451–461.
   PubMed Web of Science ®Google Scholar
• Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia. 2002;8:83–90.
   PubMed Web of Science ®Google Scholar
• Zanon E, Milan M, Brandolin B, et al. High dose of human plasma-derived FVIII-VWF as first-line therapy in patients affected by acquired haemophilia A and concomitant cardiovascular disease: four case reports and a literature review. Haemophilia. 2013;19:e50–3.
   PubMed Web of Science ®Google Scholar
• Morrison AE, Ludlam CA, Kessler C. Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood. 1993;81:1513–1520.
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Franchini M. Porcine recombinant factor VIII: an additional weapon to handle anti-factor VIII antibodies. Blood Transfus. 2017;15:365–368.
   PubMed Web of Science ®Google Scholar
• Tiede A. Critical bleeding in acquired hemophilia A: bypassing agents or recombinant porcine factor VIII? Hamostaseologie. 2020 Sept 11. DOI:10.1055/a-1171-0522
   Web of Science ®Google Scholar
• Kruse-Jarres R, St-Louis J, Greist A, et al. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia. 2015;21:162–170.
   PubMed Web of Science ®Google Scholar
• Tarantino MD, Cuker A, Hardesty B, et al. Recombinant porcine sequence factor VIII (rpFVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients. Haemophilia. 2017;23:25–32.
   PubMedGoogle Scholar
• Zanon E, Pasca S, Borchiellini A, et al. Susoctocog-alfa (Obizur®) in the treatment of nine elderly patients with acquired haemophilia A: an Italian multicentre real life experience. Blood Transfus. 2020;18:312–321.
   PubMed Web of Science ®Google Scholar
• Türkantoz H, Königs C, Knöbl P, et al. Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: data from the GTH-AH 01/2010 Study. J Thromb Haemost. 2020;18(1):36–43.
   PubMed Web of Science ®Google Scholar
• Spadarella G, Di Minno A, Milan G, et al. Paradigm shift for the treatment of hereditary haemophilia: towards precision medicine. Blood Rev. 2020;39:100618.
   PubMed Web of Science ®Google Scholar
• Franchini M, Marano G, Pati I, et al. Investigational drugs to treat hemophilia. Expert Opin Investig Drugs. 2020;29:295–301.
   PubMed Web of Science ®Google Scholar
• Franchini M, Marano G, Pati I, et al. Emicizumab for the treatment of haemophilia A: a narrative review. Blood Transfus. 2019;17:223–228.
   PubMed Web of Science ®Google Scholar
• Muto A, Yoshihashi K, Takeda M, et al. The anti-factor IXa/X bispecific antibody ACE910 prevents spontaneous joint bleeds in a long-term primate model of acquired hemophilia A. Blood. 2014;124:3165–3171.
   PubMed Web of Science ®Google Scholar
• Knoebl P, Sperr WR, Schellongowski P, et al. Emicizumab for the treatment of acquired hemophilia A: lessons learned from 4 very different cases. Blood. 2018;132(Suppl 1):2476.
   Google Scholar
• Möhnle P, Pekrul I, Spannagl M, et al. Emicizumab in the treatment of acquired haemophilia: a case report. Transfus Med Hemother. 2019;46:121–123.
   PubMed Web of Science ®Google Scholar
• Dane KE, Lindsley JP, Streiff MB, et al. Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention. Res Pract Thromb Haemost. 2019;3(3):420–423.
   PubMed Web of Science ®Google Scholar
• Al-Banaa K, Alhillan A, Hawa F, et al. Emicizumab use in treatment of acquired hemophilia A: a case report. Am J Case Rep. 2019;20:1046–1048.
   PubMed Web of Science ®Google Scholar
• Hess KJ, Patel P, Joshi AM, et al. Utilization of emicizumab in acquired factor VIII deficiency. Am J Case Rep. 2020;21:e922326.
   PubMed Web of Science ®Google Scholar
• Knoebl P, Thaler J, Jilma P, et al. Emicizumab for the treatment of acquired hemophilia A. Blood. 2020;7:blood.2020006315.
   Google Scholar
• Tiede A, Kemkes-Matthes B, Knöbl P. Should emicizumab be used in patients with acquired hemophilia A? J Thromb Haemost. 2020 Dec 11. DOI:10.1111/jth.15208
   Web of Science ®Google Scholar
• Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377:809–818.
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379:811–822.
   PubMed Web of Science ®Google Scholar